Literature DB >> 820501

Oral contraceptive, pulmonary artery thrombosis and anti-ethinyl-oestradiol monoclonal IgG.

J L Beaumont, N Lemort.   

Abstract

Pulmonary artery thrombosis and an anti-ethinyl-oestradiol monoclonal IgGlambda were found to be associated in a 36-year-old woman (Mrs MAI.) who took an oral contraceptive containing 50 mug ethinyl-oestradiol and 500 mug nor-ethisterone daily. After appropriate purification including methods by which the IgG was separated of bound circulating hormones, its binding activity was demonstrated by several methods: passive haemagglutination of oestradiol-benzoate sensitized red blood cells; gel filtration on Sephadex G-25; ultracentrifugation and equilibrium dialysis. IgGlambda MAI bound ethinyl oestradiol (Ka=2-7 X 10(1) M-1) and also 17-beta-oestradiol, with a lower affinity (Ka=0-4 X 10(7) M-1). The valency for these two hormones was near 2. Ethinyl-oestradiol bound to the IgG was displaced by ethinyl-oestradiol itself and in decreasing order of potency by 17-beta-oestradiol, progesterone, oestriol, and testosterone. Oestrone and hydrocortisone had no effect. Although the localization of the binding sites of this IgGlambda was not studied, it is likely that they were the antibody sites of the molecule and, according to immunochemical criteria, it may be classified as a monoclonal anti-ethinyl-oestradiol antibody. It is felt that its association with the pulmonary thrombosis and the oral contraceptive may be significant. This supports the hypothesis of an immunological mechanism for the unexplained thrombotic risk of oral contraceptives.

Entities:  

Keywords:  Androgens; Biology; Blood Coagulation Effects; Case Studies; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Diseases; Embolism; Endocrine System; Estradiol; Estriol; Estrogens; Ethinyl Estradiol; Family Planning; Hematological Effects; Hemic System; Hormone Receptors; Hormones; Immunoglobulin Alterations; Membrane Proteins; Norethindrone Acetate; Oral Contraceptives; Oral Contraceptives, Combined; Physiology; Progestational Hormones; Progesterone; Research Methodology; Studies; Testosterone; Thromboembolism; Thrombosis; Vascular Diseases

Mesh:

Substances:

Year:  1976        PMID: 820501      PMCID: PMC1538533     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  [Immunoelectrophoretic method for the analysis of mixtures of antigenic substances].

Authors:  P GRABAR; C A WILLIAMS
Journal:  Biochim Biophys Acta       Date:  1955-05

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Improved gel-filtration method for analysis of estrogen receptor binding.

Authors:  V C Godefroi; S C Brooks
Journal:  Anal Biochem       Date:  1973-02       Impact factor: 3.365

4.  [The specific activity of the M proteins. "Towards a new criterion for the classification of the myelomas and macroglobulinemias"].

Authors:  J L Beaumont
Journal:  Rev Fr Etud Clin Biol       Date:  1967-04

5.  Antibody activity of human myeloma globulins.

Authors:  M Seligmann; J C Brouet
Journal:  Semin Hematol       Date:  1973-04       Impact factor: 3.851

6.  Oral contraceptive side-effects and allergy: an immune etiology?

Authors:  F D Abramson; J S Schultz
Journal:  Lancet       Date:  1971-12-18       Impact factor: 79.321

7.  Rheumatic symptoms and serological abnormalities induced by oral contraceptives.

Authors:  G G Bole; M H Friedlaender; C K Smith
Journal:  Lancet       Date:  1969-02-15       Impact factor: 79.321

8.  L.E. cells after oral contraceptives.

Authors:  E L DuBois; L Strain; M Ehn; G Bernstein; G J Friou
Journal:  Lancet       Date:  1968-09-21       Impact factor: 79.321

9.  [Passive hemagglutination with chromium chloride. Its use without macromolecular dilution].

Authors:  J L Beaumont; M F Baudet; B Delplanque; F Péron
Journal:  Pathol Biol (Paris)       Date:  1969-04

10.  Thromboembolism and oral contraceptives: an epidemiologic case-control study.

Authors:  P E Sartwell; A T Masi; F G Arthes; G R Greene; H E Smith
Journal:  Am J Epidemiol       Date:  1969-11       Impact factor: 4.897

View more
  6 in total

Review 1.  Hormonal steroid contraceptives: a further review of adverse reactions.

Authors:  E G McQueen
Journal:  Drugs       Date:  1978-10       Impact factor: 9.546

2.  Antiethinyloestradiol antibody activities in oral contraceptive users.

Authors:  J L Beaumont; N Lemort; L Lorenzelli-Edouard; B Delplanque; V Beaumont
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

Review 3.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

4.  Cerebral infarction in young people. A study of 148 patients with early cerebral angiography.

Authors:  F Lisovoski; P Rousseaux
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-07       Impact factor: 10.154

5.  Immunogenicity and the vascular risk of oral contraceptives.

Authors:  C Plowright; S A Adam; M Thorogood; V Beaumont; J L Beaumont; J I Mann
Journal:  Br Heart J       Date:  1985-05

6.  Cyclodextrin-Functionalized Fiber Yarns Spun from Deep Eutectic Cellulose Solutions for Nonspecific Hormone Capture in Aqueous Matrices.

Authors:  Hannes Orelma; Tommi Virtanen; Steven Spoljaric; Jani Lehmonen; Jukka Seppälä; Orlando J Rojas; Ali Harlin
Journal:  Biomacromolecules       Date:  2018-02-02       Impact factor: 6.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.